Adamas Pharmaceuticals (ADMS) PT Raised to $37 at Credit Suisse

Credit Suisse analyst V. Divan reiterated an Outperform rating and raised its price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $37.00 (from $35.00) after raising the probability of success for ADS-5102 to 90% (from 80%) on the back of encouraging topline phase 3 data for their lead internal asset ADS-5102 in levodopainduced dyskinesia (LID) in patients With Parkinson's Disease.

Shares of ADMS surged 83% Wednesday as news broke

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $30.85 yesterday.

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Southern Co. (SO) PT Lowered to $99 at Jefferies